Teprotumumab and sensorineural hearing loss: a propensity score-matched retrospective cohort study.

ABSTRACT: Teprotumumab, a monoclonal antibody that antagonizes the insulin-like growth factor 1 receptor, is the first medication within the United States to receive Food and Drug Administration (FDA) approval for thyroid eye disease (TED). The FDA recently issued a warning regarding otologic complications, such as hearing loss. We aimed to study the association between teprotumumab and sensorineural hearing loss in thyrotoxic patients with TED. A real-world retrospective cohort study was performed through the TriNetX Collaborative Network (globally de-identified database) over a 5-year period. Inclusion criteria were patients at least 18 years of age with a diagnosis of Graves' disease and TED, and were stratified into two cohorts: those treated with teprotumumab and those who were not. Propensity

SUBMITTER: Barnett MJL 

PROVIDER: S-EPMC12323317 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature